These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38934228)

  • 1. An updated reappraisal of dupilumab in children and adolescents with moderate-severe atopic dermatitis.
    Ciprandi G; Licari A; Tosca MA; Miraglia Del Giudice M; Belloni Fortina A; Marseglia GL
    Pediatr Allergy Immunol; 2024 Jun; 35(6):e14181. PubMed ID: 38934228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dupilumab for the treatment of adolescents with atopic dermatitis.
    Senner S; Seegräber M; Frey S; Kendziora B; Eicher L; Wollenberg A
    Expert Rev Clin Immunol; 2020 Jul; 16(7):641-650. PubMed ID: 32720530
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Updated Reappraisal of Dupilumab in Children and Adolescents with Severe Asthma.
    Marseglia GL; Licari A; Tosca MA; Miraglia Del Giudice M; Indolfi C; Ciprandi G
    Children (Basel); 2024 Jul; 11(7):. PubMed ID: 39062292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study.
    Paller AS; Siegfried EC; Simpson EL; Cork MJ; Sidbury R; Chen IH; Khokhar FA; Xiao J; Dubost-Brama A; Bansal A
    Am J Clin Dermatol; 2024 Jul; 25(4):655-668. PubMed ID: 38743155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy.
    D'Erme AM; Romanelli M; Chiricozzi A
    Drug Des Devel Ther; 2017; 11():1473-1480. PubMed ID: 28553077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weight gain in patients with severe atopic dermatitis treated with dupilumab: a cohort study.
    Johansson EK; Ivert LU; Bradley B; Lundqvist M; Bradley M
    BMC Dermatol; 2020 Sep; 20(1):8. PubMed ID: 32962676
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dupilumab: human monoclonal antibody against IL-4Rα for moderate to severe atopic dermatitis.
    Paton DM
    Drugs Today (Barc); 2017 Sep; 53(9):477-487. PubMed ID: 29238761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologics for Atopic Dermatitis.
    Boguniewicz M
    Immunol Allergy Clin North Am; 2020 Nov; 40(4):593-607. PubMed ID: 33012322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dupilumab: A review of its use in the treatment of atopic dermatitis.
    Gooderham MJ; Hong HC; Eshtiaghi P; Papp KA
    J Am Acad Dermatol; 2018 Mar; 78(3 Suppl 1):S28-S36. PubMed ID: 29471919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dupilumab in the treatment of moderate-to-severe atopic dermatitis.
    Kraft M; Worm M
    Expert Rev Clin Immunol; 2017 Apr; 13(4):301-310. PubMed ID: 28165826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE).
    Blauvelt A; Guttman-Yassky E; Paller AS; Simpson EL; Cork MJ; Weisman J; Browning J; Soong W; Sun X; Chen Z; Kosloski MP; Kamal MA; Delevry D; Chuang CC; O'Malley JT; Bansal A
    Am J Clin Dermatol; 2022 May; 23(3):365-383. PubMed ID: 35567671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children.
    Wang M; Gao XH; Zhang L
    Drug Des Devel Ther; 2024; 18():941-951. PubMed ID: 38560522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches.
    Moyle M; Cevikbas F; Harden JL; Guttman-Yassky E
    Exp Dermatol; 2019 Jul; 28(7):756-768. PubMed ID: 30825336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Dupilumab Treatment with Concomitant Topical Corticosteroids in Children Aged 6 Months to 5 Years with Severe Atopic Dermatitis.
    Paller AS; Pinter A; Wine Lee L; Aschoff R; Zdybski J; Schnopp C; Praestgaard A; Bansal A; Shumel B; Prescilla R; Bastian M
    Adv Ther; 2024 Mar; 41(3):1046-1061. PubMed ID: 38194047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
    Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
    Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis.
    Silverberg JI; Kantor R
    Dermatol Clin; 2017 Jul; 35(3):327-334. PubMed ID: 28577802
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dupilumab for Moderate-to-Severe Atopic Dermatitis.
    Vangipuram R; Tyring SK
    Skin Therapy Lett; 2017 Nov; 22(6):1-4. PubMed ID: 29091379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Dupilumab.
    Harb H; Chatila TA
    Clin Exp Allergy; 2020 Jan; 50(1):5-14. PubMed ID: 31505066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Rapid response to dupilumab treatment in children with moderate-to-severe atopic dermatitis: A case series.
    Votto M; Delle Cave F; De Filippo M; Marseglia A; Marseglia GL; Brazzelli V; Licari A
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27(Suppl 27):31-33. PubMed ID: 35080304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dupilumab: Mechanism of action, clinical, and translational science.
    McCann MR; Kosloski MP; Xu C; Davis JD; Kamal MA
    Clin Transl Sci; 2024 Aug; 17(8):e13899. PubMed ID: 39080841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.